AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Meanwhile, Tango tries again in PRMT5.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Halda, Accent and Vividion take more projects into phase 1.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Opdualag chalks up another failure, this time in the extension of an approved use.
